Citi upgraded Intuitive Surgical (ISRG) to Buy from Neutral with an unchanged price target of $590. The firm believes fundamentals in the U.S. medical technology sector remain “healthy” despite the recent volatility. Shares of Intuitive have fallen with the market, but the company is well positioned to grow sales at a double-digit pace while leveraging earnings, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical upgraded to Buy from Neutral at Citi
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors
- Intuitive Surgical Expands Direct Robotic Operations in Southern Europe
- Intuitive Surgical announces U.S. FDA cleared da Vinci 5 system
- Intuitive Surgical price target lowered to $570 from $600 at UBS